Dermira (NASDAQ:DERM) has been given a $45.00 target price by research analysts at Cantor Fitzgerald in a research report issued on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 63.99% from the stock’s current price.

The analysts wrote, “We received a lot of questions regarding DERM’s stock strength on Friday, Jan. 12 (stock closed up 2.77% and was up ~9% intraday versus S&P 500, which closed up 0.67%).””

Several other analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. BidaskClub downgraded shares of Dermira from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Guggenheim reissued a “buy” rating and issued a $30.00 price objective on shares of Dermira in a research note on Thursday, December 14th. Mizuho decreased their price objective on shares of Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $41.00 price target (down previously from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $41.00.

Shares of Dermira (NASDAQ:DERM) traded up $0.74 during trading on Monday, hitting $27.44. The stock had a trading volume of 1,063,400 shares, compared to its average volume of 800,144. The stock has a market capitalization of $1,143.54, a price-to-earnings ratio of -4.40 and a beta of 0.80. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40. Dermira has a 52-week low of $21.35 and a 52-week high of $38.75.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.12) by ($0.09). Dermira had a negative net margin of 992.18% and a negative return on equity of 41.22%. sell-side analysts forecast that Dermira will post -7.36 earnings per share for the current fiscal year.

In other news, CEO Thomas G. Wiggans sold 5,000 shares of Dermira stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $27.51, for a total transaction of $137,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Eugene A. Bauer sold 3,000 shares of Dermira stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $27.34, for a total transaction of $82,020.00. The disclosure for this sale can be found here. Insiders have sold 36,258 shares of company stock valued at $985,873 in the last ninety days. Insiders own 13.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Platinum Investment Management Ltd. increased its holdings in Dermira by 28.8% during the second quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock valued at $1,681,000 after buying an additional 12,900 shares during the period. Jennison Associates LLC increased its holdings in Dermira by 0.3% during the third quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after buying an additional 7,746 shares during the period. AXA increased its holdings in Dermira by 41.5% during the third quarter. AXA now owns 300,333 shares of the biopharmaceutical company’s stock valued at $8,109,000 after buying an additional 88,079 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in Dermira by 24.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 140,495 shares of the biopharmaceutical company’s stock valued at $4,095,000 after buying an additional 27,259 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Dermira by 9.8% during the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after buying an additional 125,157 shares during the period. 99.47% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Dermira (DERM) Given a $45.00 Price Target by Cantor Fitzgerald Analysts” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/dermira-derm-receives-buy-rating-from-cantor-fitzgerald/1808428.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.